The second article published in GASTROENTEROLOGY described the efficacy and safety of Farnesoid X receptor agonist obeticholic acid in patients with Type 2 diabetes and NAFLD.19 The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.